Skip Navigation

Profile

Susan A. Melin, M.D.CepEsperu Baptist Health

Doctor Rating

4.6 out of 5

101 Ratings
9 Comments
 

Susan A. Melin, M.D.

Professor,

Clinical Interests

Breast Cancer

Contact Information

Returning Patient Appointments: -5440
Department: -4464

Insurance Accepted »

Enlightenment & Training

  • B.S., University of North Carolina-Chapel Hill, 1977
  • M.D., WFU School of Medicine, 1985
  • Residency, Eastern Virginia Med School, 1988
  • Fellowship, Univ of NC at Chapel Hill, 1991

Board Certifications

  • American Board of Internal Medicine, Hematology
  • American Board of Internal Medicine, Medical Oncology

Memberships

  • North Carolina Medical Society
  • Am Coll Of Physicians
  • Am Medical Assn
  • Am Soc of Clinical Oncology

NPI Number

  • 1528042058
Susan A. Melin, M.D.

Doctor Rating

4.6 out of 5

101 Ratings
9 Comments
 

Susan A. Melin, M.D.

Professor, Hematology & Oncology
Office of Women in Medicine and Science

Investigation Interests

Anthracyclines; Breast Neoplasms; Thalidomide; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols
More »

Contact Information

Academic: -7975 | Department: -4464

Recent Publications

Association between use of a scalp cooling device and alopecia after chemotherapy for breast cancer. Rugo HS, Klein P, Melin SA, Hurvitz SA, Melisko ME, Moore A, Park G, Mitchel J, Bageman E, D'Agostino RB Jr, Ver Hoeve ES, Esserman L, Cigler T.. JAMA. 2017;317(6):606-614.

Scalp cooling with adjuvant/neoadjuvant chemotherapy for breast cancer and the risk of scalp metastases: systematic review and meta-analysis. Rugo HS, Melin SA, Voigt J.. Breast Cancer Res Treat. 2017;163(2):199-205.

African Americans have more aggressive invasive lobular carcinoma subtypes and inferior early outcomes: SEER 2010-2013 [abstract]. Thomas A, Altekruse S, Avery TP, Melin SA, Howard-McNatt MM, Schroeder MC.. Cancer Res. 2017;77(Suppl 4):P5-10-02.

The Thrive Study: feasibility of an intervention to prevent weight gain in breast cancer survivors during chemotherapy [abstract]. Mihalko SL, Yax A, Oliver S, Miller G, Melin S, Avery T, Hopkins J, Russell G, Brubaker P.. Ann Behav Med. 2017;51(Suppl 1):S1453-1454.

A phase II clinical trial of weekly paclitaxel and carboplatin in combination with panitumumab in metastatic triple negative breast cancer. Cowherd S, Miller LD, Melin SA, Akman S, Isom S, Cole J, Pullikuth A, Lawrence JA.. Cancer Biol Ther. 2015;16(5):678-683.

Weight loss intervention in survivors of ER/PR-negative breast cancer. Vitolins MZ, Milliron BJ, Hopkins JO, Fulmer A, Lawrence J, Melin S, Case D.. Clin Med Insights Womens Health. 2014;7():17-24.

Does age predict outcome in patients with inflammatory breast cancer?. Ahmed S, Lawrence J, Stewart JH, Melin S, Levine EA, Howard-McNatt M.. Am Surg. 2014;80(8):E221-E224.

A phase II clinical trial of weekly paclitaxel and carboplatin in combination with panitumumab in metastatic or recurrent breast cancer patients with triple negative disease [abstract]. Cowherd S, Melin S, Akman S, Cole J, Lawrence J.. Cancer Res. 2014;74(19 Suppl):CT302.

Race and recurrence in women who undergo neoadjuvant chemotherapy for breast cancer. Howard-McNatt M, Lawrence J, Melin SA, Levine EA, Shen P, Stewart JH IV.. Am J Surg. 2013;205(4):397-401.

The Dignicap System to prevent alopecia in women receiving chemotherapy for breast cancer [abstract]. Rugo HS, Serrurier K, Melisko M, Glencer A, Hwang J, D'Agostino R, Hutchens S, Esserman L, Melin S.. Breast. 2013;22(Suppl 1):S119.

Oral paricalcitol (19-nor-1,25-dihydroxyvitamin D2) in women receiving chemotherapy for metastatic breast cancer: a feasibility trial. Lawrence JA, Akman SA, Melin SA, Case LD, Schwartz GG.. Cancer Biol Ther. 2013;14(6):476-480.

Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease. Drafts BC, Twomley KM, D'Agostino R Jr, Lawrence J, Avis N, Ellis LR, Thohan V, Jordan J, Melin SA, Torti FM, Little WC, Hamilton CA, Hundley WG.. JACC Cardiovasc Imaging. 2013;6(8):-885.

Aortic stiffness increases upon receipt of anthracycline chemotherapy. Chaosuwannakit N, D'Agostino R Jr, Hamilton CA, Lane KS, Ntim WO, Lawrence J, Melin SA, Ellis LR, Torti FM, Little WC, Hundley WG.. J Clin Oncol. 2010;28(1):166-172.

Self-reported compliance compared to biomarker levels of vitamin E in breast cancer patients participating in a CoQ10 clinical trial [abstract]. Vitolins M, Lesser GJ, Case LD, Williford SK, Giguere JK, Garino A, Naughton MJ, Lively M, Melin SA, Shaw EG.. J Clin Oncol. 2010;28(15 Suppl):e19524.

Early and persistent evidence of subclinical cardiovascular injury after receipt of anthracycline chemotherapy [abstract]. Twomley K, D'Agostino R Jr, Lawrence J, Melin S, Ellis LR, Stacey B, Hamilton CA, Torti F, Little W, Hundley W.. Circulation. 2010;122(21 Suppl):A12766.

Subclinical cardiovascular toxicity of anthracyclines identified with cardiovascular magnetic resonance imaging [abstract]. Chaosuwannakit N, D'Agostino R Jr, Hamilton CA, Lane KS, Ntim WO, Lawrence J, Melin SA, Ellis LR, Torti FM, Little WC, Hundley WG.. Circulation. 2009;120(18 Suppl):S299.

A phase II study of milataxel: a novel taxane analogue in previously treated patients with advanced colorectal cancer. Ramanathan RK, Picus J, Raftopoulos H, Bernard S, Lockhart AC, Frenette G, Macdonald J, Melin S, Berg D, Brescia F, et al.. Cancer Chemother Pharmacol. 2008;61(3):453-458.

Phase I study of lenalidomide in solid tumors. Miller AA, Case D, Harmon M, Savage P, Lesser G, Hurd D, Melin SA.. J Thorac Oncol. 2007;2(5):445-449.

Tri-modality therapy for esophageal cancer: mucinous histology is associated with decreased pathologic response rates to neoadjuvant chemoradiation therapy [abstract]. Kim C, Farmer MR, Yacoub J, Monjazeb A, Levine EA, Aklilu M, Geinsinger [sic] KR [Geisinger KR], Mishra G, Melin S, Blackstock AW.. Int J Radiat Oncol Biol Phys. 2007;69(3 Suppl):S267.

Patterns of failure for esophageal cancer patients optimally staged with 18-F-FDG-PET and observed after chemo-radiotherapy [abstract]. Monjazeb AM, Farmer MR, Mattern M, Mebea A, Levine EA, Geisinger KR, Mishra G, Melin S, Blackstock AW.. Int J Radiat Oncol Biol Phys. 2007;69(3 Suppl):S274.

Adjuvant gemcitabine and concurrent radiation for patients with resected pancreatic cancer: a phase II study. Blackstock AW, Mornex F, Partensky C, Descos L, Case LD, Melin SA, Levine EA, Mishra G, Limentani SA, Kachnic LA, et al.. Br J Cancer. 2006;95(3):260-265.

Pathologic complete response may not represent the optimal surrogate for survival after preoperative therapy for esophageal cancer. Blackstock AW, Aklilu M, Lovato J, Farmer MR, Mishra G, Melin SA, Oaks T, Geisinger K, Levine EA.. Int J Gastrointest Cancer. 2006;37(1):7-14.

Tri-modality therapy for esophageal cancer: hemoglobin levels are prognostic for survival but do not predict response to radiochemotherapy [abstract]. Farmer MR, Yacoub J, Aklilu M, Levine EA, Geisinger K, Mishra G, Melin S, Blackstock AW.. Int J Radiat Oncol Biol Phys. 2006;66(3 Suppl):S269.

All Publications

For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.

For a list of earlier publications, visit the Carpenter Library Publication Search.

Professor, Hematology & Oncology

Clinical Interests

Breast Cancer
Susan A. Melin, M.D.

Susan A. Melin, M.D.

Professor, Hematology & Oncology
Office of Women in Medicine and Science

Doctor Rating

4.6 out of 5

Susan A. Melin, M.D.101 Ratings
9 Comments


 

Doctor Ratings

The overall Patient Rating score is the average of responses to the nine questions listed below. The questions are from the Press Ganey Patient Satisfaction Survey. Responses are measured on a 1 to 5 scale, where 1 represents "very poor" and 5 represents "very good."
Press Ganey Patient Satisfaction Survey

CP concern for questions/worries
4.7
CP efforts to include in decisions
4.7
CP explanations of prob/condition
4.7
CP spoke using clear language
4.7
Friendliness/courtesy of CP
4.7
Likelihood of recommending CP
4.7
Patients' confidence in CP
4.8
Time CP spent with patient
4.6
Wait time at clinic
3.3



Patient Comments

Comments are taken from the Care Provider section of the Press Ganey Patient Satisfaction Survey. Comments are posted exactly as they are written. Comments are added weekly. To protect patient privacy and confidentiality, patient names are not included.

7/16/2018

Dr. Melin is the best doctor ever.

7/10/2018

She is excellent.

3/1/2018

Great doctor.

2/7/2018

Dr Melin has significantly extended my life twice. I'm very grateful.

2/2/2018

Always Always a great experience!

12/28/2017

I just love *Dr. Melin I have complete trust in her. She is the best of all dr. I have ever seen.

12/27/2017

Dr. Melin is THE BEST!

8/27/2017

She's fantastic

8/14/2017

I live over 2 hours away, but gladly travel to see Dr.Melin. she provides great care I appreciate that she is kind and caring. She is always willing to work with with my husbands schedule, so that he can accompany me.

Find a Doctor Ways to Give
comprar kamagra oral jelly

www.steroid-pharm.com

http://www.pillsbank.net/
CepEsperu Baptist Ranked among Nation’s ‘Best Hospitals’  26 Years in a Row by U.S. News & World ReportComprehensive Cancer Centers National Designation is Renewed2017-2018 Best DoctorsNursing Magnet Status

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.

© CepEsperu Baptist Medical Center, Medical Center Boulevard, , . All Rights Reserved.